Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Atherotech Diagnostics Lab will exhibit its VAP Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update.

26 Aug 2010

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting.

26 Aug 2010

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Researchers at Massachusetts General Hospital found that patients with nonalcoholic fatty liver disease (NAFLD) who carry an allele of the PNPLA3 gene have an increased risk of developing advanced disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A second study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) validates these findings and further concludes that in pediatric patients, the same allele is associated with earlier disease presentation.

18 Aug 2010

Research confirms genetic link to advanced fatty liver disease

17 Aug 2010

Thickening of neck artery wall increases risk of heart attack, stroke: Study

Researchers for the U.S. National Institute on Aging (NIA), a component of the National Institutes of Health (NIH), studied 5,614 Italians in four villages and found that those who scored high for antagonistic traits on a standard personality test had greater thickening of the neck (carotid) arteries compared to people who were more agreeable. Thickness of neck artery walls is a risk factor for heart attack and stroke.

17 Aug 2010

Kaiser Permanente uses integrated care delivery model to aid mothers understand benefits of breastfeeding

August is National Breastfeeding Awareness Month, and Kaiser Permanente believes that one of the most important choices a mother can make to promote the health of her family is to choose to breastfeed exclusively. Kaiser Permanente, with more than 90,000 births in 2009, uses its integrated care delivery model to help mothers understand the benefits of breastfeeding to both mother and child and support the mother's infant feeding decision.

16 Aug 2010

Childhood brain tumor survivors may be vulnerable to physical declines associated with aging: Study

A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.

16 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Research findings show normal rise and fall in triglycerides

When the circadian rhythm gets thrown off, it could come with an unexpected side effect: high triglycerides. The discovery, based on studies in mice with a "broken clock," helps to explain the normal rise and fall in triglycerides, which happens at about the same time each day, according to researchers who report their findings in the August issue of Cell Metabolism, a Cell Press publication.

4 Aug 2010

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status.

2 Aug 2010

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.

30 Jul 2010

Obesity linked to early puberty in girls

A review of more than 100 studies found overweight girls tend to reach puberty earlier than their peers do.

26 Jul 2010

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Boehringer Ingelheim announced today that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses.

26 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

California companies are developing new medicines for diabetes: Report

Pharmaceutical research and biotechnology companies based in California are researching and developing 58 new medicines for diabetes, a chronic disease that afflicts 220 million patients worldwide, including 23.6 million Americans, a new report shows.

21 Jul 2010

Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

Latest achievements in brain research and treatment for mental disorders

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Thickening of neck artery wall increases risk of heart attack, stroke: Study

Kaiser Permanente uses integrated care delivery model to aid mothers understand benefits of breastfeeding

Childhood brain tumor survivors may be vulnerable to physical declines associated with aging: Study

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Research findings show normal rise and fall in triglycerides

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Obesity linked to early puberty in girls

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

California companies are developing new medicines for diabetes: Report

eBook: Integrated solutions for metabolic disease drug development eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

eBook: Integrated solutions for metabolic disease drug development eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in